ARC186 is a highly potent aptamer that serves as a complement inhibitor by blocking the convertase-catalyzed activation of C5.

ARC1905, a non-PEGylated/naked anti-C5 RNA aptamer, functions by inhibiting the cleavage of complement factor 5 (C5) into its components, C5a and C5b, without PEG conjugation. This compound is currently being researched for its potential application in the treatment of age-related macular degeneration (AMD).

NH2-C6-ARC186 is a derivative of the aptamer ARC186, featuring an NH2-C6 moiety that enables coupling to various peptides or molecules. As a potent complement inhibitor, it operates by inhibiting convertase-mediated C5 activation [1].

ARC19499, an aptamer, inhibits the tissue factor pathway inhibitor (TFPI), facilitating clot initiation and propagation through the extrinsic pathway. It binds specifically to TFPI, blocking its inhibition of both factor Xa and the TF/factor VIIa complex, thereby correcting thrombin generation in hemophilia A and B plasma and restoring clotting in FVIII-neutralized whole blood.